Skip to content

  • About me
  • Research & Publications
  • Useful links

wacc

November 6, 2016 Return to: Brand Valuation of OTC Pharmaceutical BusinessesFull resolution (864 × 609)

Image navigation

Previous Image

Share this:

  • LinkedIn
  • Twitter
  • Facebook
  • Print
  • Tumblr

Like this:

Like Loading...
View Demetris Iacovides's profile on LinkedIn


Dimitris uses its unique blend of studies in Management and Biotech combined with his quick witted entrepreneurial spirit to give small business owners in the Pharmaceutical industry, reliable advice and direction to make their businesses financially and strategically sustainable.

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 127 other followers

Recent Posts

  • Is the Celgene / Amgen deal for Otezla fair?
  • Biotech rNPV Valuation using Monte Carlo simulation – A simple approach
  • Is Novartis leading the way in pharma R&D restructuring?
  • Can U.S. Drug Prices be Justified? A U.S. vs. E.U. Comparison
  • A Simple Licensing Deal Model for your Biotech Start-Up

Recent Comments

Isabelle on Can U.S. Drug Prices be Justif…

Categories

  • Finance
  • Strategy
  • Uncategorised

Archives

  • October 2019
  • August 2019
  • November 2018
  • March 2017
  • December 2016
  • November 2016
  • October 2016
  • August 2016
  • November 2015
  • July 2015
  • December 2014
  • October 2014
  • July 2014
  • May 2014
  • April 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • March 2013
  • February 2013

AstraZeneca balance sheet items biotechnology current liabilities effective tax rate free cash flow free cash flow calculation patent expiry Pfizer valuation valuation methodologies value and risk

Blog Stats

  • 125,489 hits
Blog at WordPress.com.
%d bloggers like this: